Strides Pharma Science shareholding pattern

STAR

869.65

0.55 (-0.06%)
Last updated on 20 Feb, 2026 | 15:57 IST
alert_iconwatchlist_icon
BUYSELL
Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Strides Pharma Science Shareholding Pattern

  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2019-20
  • 2018-19
Total Promoters
Segment
Percent

Total Promoters

30.89%

Mutual Fund

11.65%

Insurance

5.26%

Foreign Institutional Investors

18.93%

Domestic Institutional Investors

1.99%

Retail

31.28%

Others

0%

Total Promoters
MAR '22
30.6%
JUN '22
30.37%
SEP '22
31.07%
DEC '22
30.89%

Summary

For Year 2025-26, Strides Pharma Science reports the following shareholding: Total Promoters at 27.86%, Mutual Fund at 8.59%, Insurance at 3.05%, Foreign Institutional Investors at 29.52%, Domestic Institutional Investors at 1.39%, and Retail at 29.59%. This breakdown provides a quick snapshot of ownership distribution for Strides Pharma Science in 2025-26.

Strides Pharma Science FAQs

As of 02-2026, the promoter shareholding in Strides Pharma Science stands at 27.86% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Strides Pharma Science is 29.52% and 1.39% respectively.

The retail shareholding of the Strides Pharma Science is 29.59%.

Changes in shareholding patterns of Strides Pharma Science can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Strides Pharma Science are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost